Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2831157 | 0.99 | KDM4E (0.52) | KDM4EGLAGAAHTTCASR | |
| SCHEMBL457098 | 0.86 | INSR (0.46) | CASRINSRIGF1RMETALK | |
| Hydrochloric Acid SCHEMBL2838059 | 0.85 | INSR (0.45) | KDM4ECASRINSRIGF1RMET | |
| SCHEMBL454336 | 0.78 | MEN1 (0.53) | KDM4ECASRINSRIGF1RMET | |
| SCHEMBL456887 | 0.78 | INSR (0.42) | KDM4EGAACASRINSRIGF1R | |
| SCHEMBL22448225 | 0.78 | INSR (0.42) | KDM4EINSRIGF1RMETALK | |
| SCHEMBL2830308 | 0.78 | KDM4E (0.52) | KDM4EHTTINSRIGF1RMET | |
| SCHEMBL10207469 | 0.77 | KDM4E (0.60) | KDM4EGLAGAAHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL2832650 | 0.77 | MEN1 (0.53) | KDM4ECASRINSRIGF1RMET | |
| Hydrochloric Acid SCHEMBL2832976 | 0.77 | INSR (0.41) | KDM4EGAACASRINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552440-A1 | NOVEL COMBINATION AND USE | Helperby Therapeutics Limited (GB) | 2013-02-06 | — | — | EP | claimed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | claimed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| CN-101594866-A | The preparation of local usefulness | HELPERBY THERAPEUTICS LTD (GB) | 2009-12-02 | — | — | CN | claimed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| CN-101351203-A | Application of pyrroloquinoline compound in killing clinically latent microorganisms | HELPERBY THERAPEUTICS LTD (GB) | 2009-01-21 | — | — | CN | claimed |
| EP-1945211-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007054693-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| EP-3228314-B1 | SULOCTIDIL FOR USE TO TREAT MICROBIAL INFECTIONS | HELPERBY THERAPEUTICS LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10265373-B2 | Pharmaceutical composition and method of treating a microbial infection with sulcotidil | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| WO-2018162928-A1 | METHOD FOR RESTORING EFFICACY OF AN ANTIBACTERIAL AGENT | HELPERBY THERAPEUTICS LIMITED (GB) | 2018-09-13 | — | — | WO | disclosed |
| US-9789101-B2 | Methods and compositions for treating microbial infection using pyrroloquinone | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-3228314-A1 | VASODILATOR FOR USE TO TREAT MICROBIAL INFECTIONS | Helperby Therapeutics Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| WO-2012032360-A2 | NOVEL USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| CN-101594866-A | The preparation of local usefulness | HELPERBY THERAPEUTICS LTD (GB) | 2009-12-02 | — | — | CN | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| CN-101351203-A | Application of pyrroloquinoline compound in killing clinically latent microorganisms | HELPERBY THERAPEUTICS LTD (GB) | 2009-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | KDM4E 1494/4885GLA 53/4885GAA 373/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | KDM4E 1494/4885GLA 53/4885GAA 373/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | KDM4E 2890/4885GLA 35/4885GAA 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.